期刊文献+

序贯疗法根除幽门螺杆菌的疗效观察 被引量:3

Sequential therapy with esomeprazole in the efficacy of anti-Helicobacter pylori
下载PDF
导出
摘要 目的:观察序贯疗法根除幽门螺杆菌的疗效,探讨提高幽门螺杆菌根除率的有效方法。方法:我院2010年2月~12月间经胃镜病理及快速尿素酶试验诊断幽门螺杆菌阳性589例,其中第一次根除Hp治疗失败患者102例。将其随机分为治疗组和对照组。治疗组(50例)采用埃索美拉唑+阿莫西林+克拉霉素+替硝唑的序贯疗法治疗,对照组(52例)采用埃索美拉唑+可乐必妥+克拉霉素+替硝唑的标准四联疗法治疗。结果:治疗后停药4周复查,治疗组的临床有效率(92%)显著高于对照组(73%)(P〈0.05)。治疗组复查Hp,48例阴性,2例阳性,根除率96%。对照组复查Hp,36例阴性,16例阳性,根除率为69.2%。2组间根除率存在显著性差异(P〈0.05)。结论:最新的序贯疗法是一个高效的根除方案。 Objective:To explore the effect of sequential therapy on improving Helicobacter pylori(Hp)eradica- tion rate and reducing the recurrence.Methods:From February 2010 to December 2010,Hp positive patients were 589 in the hospital through the menstrual gastro-endoseopic pathological and rapid urease test diagnosis. In this paper,after the first time for anti-Hp treatment,102 cases were still positive.They were randomly divid- ed into sequential therapy treatment group (50 cases)and control group (52 cases)The treatment group were treated with esomeprazole+amoxicillin+clarithromycin+tinidazole sequential therapy,in the control group with es- omeprazole +levofloxaein+elarithromyein +tindazole therapy.Results :After treatment,clinical total effective rate of treatment group (92%)was significantly higher than that of control group (73% ,P〈0.05).After treatment,the treatment group review Hp,48 were negative,2 were positive ,eradication rate was 96%.The control group re- view Hp,36 were negative,16 eases were positive,eradication was 69.2%.Eradication rate between the two groups had significant differences (P〈O.OS).Conclusion:The latest treatments sequential therapy is a highly ef- fective eradication program and has broad prospects for treatment.
出处 《中日友好医院学报》 2012年第6期323-325,共3页 Journal of China-Japan Friendship Hospital
关键词 幽门螺杆菌 治疗 序贯疗法 Helicobacter pylori treatment sequential therapy
  • 相关文献

参考文献9

  • 1吕农华,祝荫.幽门螺杆菌耐药的现状与对策[J].中华消化杂志,2011,31(1):66-68. 被引量:69
  • 2O'Connor A,Gisbert J,O'Morain C.Treatment of Helicobac- ter pylori infection[J].Helicobacter,2009,14 Suppl 1:46-51.
  • 3Malfertheiner P,Megaud F,O'Morain C,et al.Current con- cepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report [J].Gut,2007,56(6): 772-781.
  • 4Raymond J,Lamarque D.Kalach N,et al.High level of an- timicrobial resistance in French Helicobacter pylori isolates [J].Helicobacter, 2010,15 : 21-27.
  • 5Kwon DH,EI-Zaatari FA,Kato M,et al.Analysis of rdxA and involvement of additional genes encoding NAD (P)H flavin oxidoreductase (FrxA)and ferredoxin-like protein (FdxB)in metronidazole resistance of Helicobacter pylori[J]. Antimicrob Agents Chemother,2000,44(8):2133-2142.
  • 6Bode G,Mauch F,Malfertheiner P.The coccoid forms of He- licobacter pylori.Criteria for their viability [J].Epidemiol In- fect, 1993,111 (3) :483-490.
  • 7陈羽,吴礼浩,何兴祥.中国序贯疗法与三联疗法治疗幽门螺杆菌感染荟萃分析[J].世界华人消化杂志,2009,17(32):3365-3369. 被引量:52
  • 8Vaira D,Zullo A,Vakil N,et al.Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradica- tion:a randomized trial [J].Ann Intern Med,2007,146(8): 556-563.
  • 9陈玉英.埃索美拉唑序贯疗法在抗HP中的疗效观察[J].中国医药指南,2012,10(2):30-31. 被引量:1

二级参考文献27

  • 1赵大国,孙玉平,潘建军.10日序贯疗法根除幽门螺杆菌的疗效观察[J].中国医师进修杂志(内科版),2006,29(10):24-25. 被引量:27
  • 2胡伏莲.《幽门螺杆菌感染若干问题共识意见》解读[J].中国医刊,2007,42(1):4-6. 被引量:51
  • 3高文,胡伏莲.幽门螺杆菌感染与胃肠道外疾病[J].中国医刊,2007,42(2):22-24. 被引量:30
  • 4萧树东,郑青.幽门螺杆菌cagA基因多态性对临床结局的影响:东亚菌株和西方菌株[J].医学与哲学(B),2007,28(6):28-31. 被引量:12
  • 5Ojetti V, Migneco A, Zocco MA, Nista EC, Gasbarrini G, Gasbarrini A. Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. J Intern Med 2004; 255:125-129.
  • 6De Francesco V, Zullo A, Hassan C, Faleo D, Ierardi E, Panella C, Morini S. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Dig Liver Dis 2001; 33:676-679.
  • 7Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi V, Perri F, Papadia C, Fomari F, Pilati S, Mete LS, Merla A, Poti R, Marinone G, Savioli A, Campo SM, Faleo D, Ierardi E, Miglioli M, Morini S. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17:719-726.
  • 8Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129:1414-1419.
  • 9Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931.
  • 10中华医学会消化病学分会幽门螺杆菌学组.第三次全国幽门螺杆菌感染若干问题共识报告.中华消化杂志,2008,:32-38.

共引文献119

同被引文献27

  • 1陈淑萍,王磊,余建奎.益生菌联合三联疗法根除幽门螺杆菌的临床研究[J].中华临床感染病杂志,2012,5(2):98-100. 被引量:42
  • 2ZuUoA,DeFranceseo V, H assan C, et al. These quential therapy regimen for Heiieohacter pylofieradication~ a pooled- data analysis[J].Gut, 2007, 56 (10) :1353.
  • 3Dino V, Angelo ZH, Nimlsh SH. Sequential therapy Versus standard triple -- drug therapy for helicobaeter pylori eradication[J]. Annals of internal Medicine, 2007,146(8) :556.
  • 4中华医学会消化病分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志,2012,10(51):832-837.
  • 5Sasaki H, Nagahara A, Hojo M, et al. Ten-year trend of the cumulative helicobacter pylori eradication rate for the Japanese eradication strategy [ J ]. Digestion, 2013, 88(4) :272-278.
  • 6Zheng X, Lyu L, Mei Z. Laetobacillus-containing pro- biotic supplementation increases helicobacter pylori e- radication rate: Evidence from a meta-analysis [ J ]. Rev Esp Enferm Dig,2013,105 (8) :445-453.
  • 7Yoon J H, Baik G H, Kim Y S, et al. Comparison of the eradication rate between 1- and 2-week bismuth-con- taining quadruple rescue therapies for helicobacter pylori eradication[ J]. Gut Liver,2012,6(4) :434-439.
  • 8Manfredi M, Bizzarri B, de' Angelis G L. Helicobacter pyIori infection: Sequential therapy followed by levoflox- acin-containing triple therapy provides a good cumulative eradication rate [ J ]. Helicobacter, 2012, 17 ( 4 ) : 246-253.
  • 9Nseir W, Diab H, Mahamid M, et al. Randomised clin- ical trial: Simvastatin as adjuvant therapy improves sig- nificantly the helicobacter pylori eradication rate-a pla- cebo-controlled study [ J ]. Aliment Pharmacol Ther, 2012,36(3) :231-238.
  • 10Kim J Y, Kim N, Park H K, et al. primary antibiotic resistance of helicobacter pylori strains and eradication rate according to gastroduodenal disease in korea [ J ]. Korean J Gastrroent-erol,2011,58 (2) :74-81.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部